Abstract

To explore the efficacy of labetalol combined with magnesium sulfate in the treatment of hypertension during pregnancy and analyze the effects of such treatment on serum pregnancy-associated plasma protein A and placental growth factor levels. 90 patients with pregnancy hypertension who were treated in our hospital from January 2020 to June 2020 were selected as research objects. Patients are randomly divided into the research group (n=45, received magnesium sulfate combined with labetalol) and the control group (n=45, simply received magnesium sulfate treatment). Then we compared the differences in blood pressure, serum pregnancyassociated plasma protein A and placental growth factor levels, and adverse reactions in the treatment of two groups. There was no statistically significant difference between the two groups of patients (p>0.05). The total incidence of adverse reactions in the study group was 6.67 % (3/45), which was significantly lower than the 24.44 % (11/45) of the patients in the control group. The incidence of neonatal suffocation, fetal distress, postpartum infection and postpartum bleeding in the research group are significantly lower than those in the control group, and the differences between the groups are statistically significant (p<0.05). The serum levels of patients in the research group with pregnancy-associated plasma protein A and placental growth factor levels were significantly higher than the control group (p<0.05). The treatment effect of hypertension during pregnancy is affirmed by the labetalol and magnesium sulfate. After treatment, patients have normal blood pressure, serum pregnancy-associated plasma protein A and placental growth factor levels have improved significantly. Furthermore, the combined treatment can effectively reduce the incidence of adverse reactions.